Ginkgo bioworks provides compensation information related to recent acquisitions

Boston , feb. 28, 2024 /prnewswire/ -- today, ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, announced that in connection to its transaction with patch biosciences, inc. ("patch bio") on february 26, 2024, ginkgo approved grants of restricted stock units with an aggregate grant date fair value of  $4,292,000 to eight patch bio employees, and in connection with its acquisition of reverie labs, inc. ("reverie") on february 23, 2024, ginkgo approved grants of restricted stock units with an aggregate grant date fair value of $3,530,000 to four reverie employees. the restricted stock units were granted without stockholder approval as material inducements to the employees entering into employment with ginkgo pursuant to nyse listed company manual section 303a.08 and were approved by the compensation committee of ginkgo's board of directors.
DNA Ratings Summary
DNA Quant Ranking